300 related articles for article (PubMed ID: 31599815)
1. Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation.
Ismail A; Sharrack B; Saccardi R; Moore JJ; Snowden JA
Curr Opin Support Palliat Care; 2019 Dec; 13(4):394-401. PubMed ID: 31599815
[TBL] [Abstract][Full Text] [Related]
2. Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists.
Das J; Sharrack B; Snowden JA
Curr Hematol Malig Rep; 2019 Apr; 14(2):127-135. PubMed ID: 30828772
[TBL] [Abstract][Full Text] [Related]
3. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.
Vaivade A; Wiberg A; Khoonsari PE; Carlsson H; Herman S; Al-Grety A; Freyhult E; Olsson-Strömberg U; Burman J; Kultima K
Lipids Health Dis; 2023 Jul; 22(1):97. PubMed ID: 37420217
[TBL] [Abstract][Full Text] [Related]
4. Healthcare utilization and costs associated with autologous haematopoietic stem cell transplantation in Norwegian patients with relapsing remitting multiple sclerosis.
Gottschlich KN; Zolic-Karlsson Z; Aas E; Kvistad SAS; Bø L; Torkildsen Ø; Lehmann AK
Mult Scler Relat Disord; 2024 Apr; 84():105507. PubMed ID: 38412758
[TBL] [Abstract][Full Text] [Related]
5. Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances.
Mariottini A; De Matteis E; Cencioni MT; Muraro PA
Curr Neurol Neurosci Rep; 2023 Sep; 23(9):507-520. PubMed ID: 37589918
[TBL] [Abstract][Full Text] [Related]
6. Autologous hematopoietic stem cell transplantation for pediatric multiple sclerosis: a registry-based study of the Autoimmune Diseases Working Party (ADWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT).
Burman J; Kirgizov K; Carlson K; Badoglio M; Mancardi GL; De Luca G; Casanova B; Ouyang J; Bembeeva R; Haas J; Bader P; Snowden J; Farge D
Bone Marrow Transplant; 2017 Aug; 52(8):1133-1137. PubMed ID: 28319075
[TBL] [Abstract][Full Text] [Related]
7. Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline.
Bayas A; Berthele A; Blank N; Dreger P; Faissner S; Friese MA; Gerdes LA; Grauer OM; Häussler V; Heesen C; Janson D; Korporal-Kuhnke M; Kowarik M; Kröger N; Lünemann JD; Martin R; Meier U; Meuth S; Muraro P; Platten M; Schirmer L; Stürner KH; Stellmann JP; Scheid C; Bergh FT; Warnke C; Wildemann B; Ziemssen T
Ther Adv Neurol Disord; 2023; 16():17562864231180730. PubMed ID: 37780055
[TBL] [Abstract][Full Text] [Related]
8. [Multiple sclerosis: interventions to halt disease : Which patients can be considered for autologous stem cell transplantation].
Willison AG; Meuth SG
Nervenarzt; 2022 Oct; 93(10):987-999. PubMed ID: 35951049
[TBL] [Abstract][Full Text] [Related]
9. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
[TBL] [Abstract][Full Text] [Related]
10. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE).
Sharrack B; Saccardi R; Alexander T; Badoglio M; Burman J; Farge D; Greco R; Jessop H; Kazmi M; Kirgizov K; Labopin M; Mancardi G; Martin R; Moore J; Muraro PA; Rovira M; Sormani MP; Snowden JA;
Bone Marrow Transplant; 2020 Feb; 55(2):283-306. PubMed ID: 31558790
[TBL] [Abstract][Full Text] [Related]
11. Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem cell transplantation.
Gakis G; Angelopoulos I; Panagoulias I; Mouzaki A
Autoimmun Rev; 2024 Feb; 23(2):103480. PubMed ID: 38008300
[TBL] [Abstract][Full Text] [Related]
12. Autologous hematopoietic stem cell transplantation (AHSCT) for aggressive multiple sclerosis - whom, when and how.
Szczechowski L; Śmiłowski M; Helbig G; Krawczyk-Kuliś M; Kyrcz-Krzemień S
Int J Neurosci; 2016 Oct; 126(10):867-71. PubMed ID: 26577419
[TBL] [Abstract][Full Text] [Related]
13. Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis.
Mancardi G; Sormani MP; Muraro PA; Boffa G; Saccardi R
Mult Scler; 2018 Mar; 24(3):245-255. PubMed ID: 29125439
[TBL] [Abstract][Full Text] [Related]
14. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
[TBL] [Abstract][Full Text] [Related]
15. Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis.
Mariottini A; Nozzoli C; Carli I; Landi F; Gigli V; Repice AM; Ipponi A; Cecchi M; Boncompagni R; Saccardi R; Massacesi L
Neurol Sci; 2024 Jul; 45(7):3379-3387. PubMed ID: 38277051
[TBL] [Abstract][Full Text] [Related]
16. Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis.
Mariottini A; Bulgarini G; Forci B; Innocenti C; Mealli F; Mattei A; Ceccarelli C; Repice AM; Barilaro A; Mechi C; Saccardi R; Massacesi L
Eur J Neurol; 2022 Jun; 29(6):1708-1718. PubMed ID: 35146841
[TBL] [Abstract][Full Text] [Related]
17. Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective.
Bose G; Thebault S; Rush CA; Atkins HL; Freedman MS
Mult Scler; 2021 Feb; 27(2):167-173. PubMed ID: 32364422
[TBL] [Abstract][Full Text] [Related]
18. Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient.
Obradović D; Tukić L; Radovinović-Tasić S; Petrović B; Elez M; Ostojić G; Balint B
Vojnosanit Pregl; 2016 May; 73(5):504-8. PubMed ID: 27430119
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis.
Ge F; Lin H; Li Z; Chang T
Neurol Sci; 2019 Mar; 40(3):479-487. PubMed ID: 30535563
[TBL] [Abstract][Full Text] [Related]
20. Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation.
Cohen JA; Baldassari LE; Atkins HL; Bowen JD; Bredeson C; Carpenter PA; Corboy JR; Freedman MS; Griffith LM; Lowsky R; Majhail NS; Muraro PA; Nash RA; Pasquini MC; Sarantopoulos S; Savani BN; Storek J; Sullivan KM; Georges GE
Biol Blood Marrow Transplant; 2019 May; 25(5):845-854. PubMed ID: 30794930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
